Tags

Type your tag names separated by a space and hit enter

Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
Expert Rev Neurother. 2015 Feb; 15(2):207-13.ER

Abstract

Dyskinesias are common, often disabling motor complications emerging in Parkinson's disease following chronic levodopa treatment. Common views associate the development of dyskinesias both with progressive loss of striatal dopamine nerve terminals and with intermittent delivery of the short half-life levodopa. Thus, according to continuous dopaminergic stimulation theory, dopamine agonists having half-lifes longer than levodopa would minimize the risk of the development of dyskinesias. The article highlights some interesting aspects of the clinical trials testing dopamine agonists monotherapy as a strategy that can reduce the risk of motor complications, and raises some concerns in terms of their early use in Parkinson's disease treatment to prevent or delay dyskinesia. Finally, we emphasize the need for reconsideration of arguments against use of levodopa as a starting therapy for Parkinson's disease.

Authors+Show Affiliations

Department of Neurology, Mediterraneo Hospital, Glyfada, Athens, Greece.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25578445

Citation

Stathis, Pantelis, et al. "Dopamine Agonists Early Monotherapy for the Delay of Development of Levodopa-induced Dyskinesias." Expert Review of Neurotherapeutics, vol. 15, no. 2, 2015, pp. 207-13.
Stathis P, Konitsiotis S, Antonini A. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. Expert Rev Neurother. 2015;15(2):207-13.
Stathis, P., Konitsiotis, S., & Antonini, A. (2015). Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. Expert Review of Neurotherapeutics, 15(2), 207-13. https://doi.org/10.1586/14737175.2015.1001747
Stathis P, Konitsiotis S, Antonini A. Dopamine Agonists Early Monotherapy for the Delay of Development of Levodopa-induced Dyskinesias. Expert Rev Neurother. 2015;15(2):207-13. PubMed PMID: 25578445.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias. AU - Stathis,Pantelis, AU - Konitsiotis,Spiridon, AU - Antonini,Angelo, Y1 - 2015/01/12/ PY - 2015/1/13/entrez PY - 2015/1/13/pubmed PY - 2015/9/19/medline KW - Parkinson’s disease KW - continuous dopaminergic stimulation KW - dopamine agonists KW - levodopa-induced dyskinesias KW - long-term results SP - 207 EP - 13 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 15 IS - 2 N2 - Dyskinesias are common, often disabling motor complications emerging in Parkinson's disease following chronic levodopa treatment. Common views associate the development of dyskinesias both with progressive loss of striatal dopamine nerve terminals and with intermittent delivery of the short half-life levodopa. Thus, according to continuous dopaminergic stimulation theory, dopamine agonists having half-lifes longer than levodopa would minimize the risk of the development of dyskinesias. The article highlights some interesting aspects of the clinical trials testing dopamine agonists monotherapy as a strategy that can reduce the risk of motor complications, and raises some concerns in terms of their early use in Parkinson's disease treatment to prevent or delay dyskinesia. Finally, we emphasize the need for reconsideration of arguments against use of levodopa as a starting therapy for Parkinson's disease. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/25578445/Dopamine_agonists_early_monotherapy_for_the_delay_of_development_of_levodopa_induced_dyskinesias_ L2 - https://www.tandfonline.com/doi/full/10.1586/14737175.2015.1001747 DB - PRIME DP - Unbound Medicine ER -